Respiratory Syncytial Virus : The race to market continues
The first wave of Ipsos’s Syndicated Global RSV study, fielded in 8 markets in Europe.
Following on from our November 2022 article, RSV: On The Verge of Change, in this short editorial we outline the current RSV landscape status, as several companies remain key contenders to launch the first vaccine.
Ipsos’ syndicated data is used to highlight key considerations affecting both physicians and consumers.
Download